JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jaguar Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$2.82−0.71 (-20.00%)
Close on Oct 19, 2026
- Market cap
- $2.28M
- P/E (TTM)
- –
- Dividend yield
- –
Jaguar Health, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Health | $11.16M | $11.37M | $9.59M | – | – | – | – | $4.12M | $1.06M | – | 96.9% | -1.9% |
| Animal Health | $353.00K | $315.00K | $173.00K | – | – | – | – | $294.23K | $3.30M | $141.52K | 3.1% | +12.1% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $11.34M | $11.56M | $9.76M | $11.96M | $4.34M | $9.39M | $5.78M | $4.24M | $1.49M | – | 98.5% | -1.9% |
| Mytesi | $11.00M | $11.30M | $9.60M | $11.70M | $4.30M | $9.30M | $5.70M | $4.12M | $1.06M | $0 | 95.6% | -2.7% |
| License | $172.00K | $129.00K | – | – | – | – | – | – | – | – | 1.5% | +33.3% |
| Canalevia-CA1 | $148.00K | $160.00K | $130.00K | $167.00K | $0 | – | – | – | – | – | 1.3% | -7.5% |
| Neonorm | $35.00K | $28.00K | $42.00K | $48.00K | $62.00K | $76.00K | $102.00K | $294.23K | $344.19K | $117.52K | 0.3% | +25.0% |
| Botanical Extract | – | – | – | – | – | – | – | $0 | $78.00K | $24.00K | – | – |
| Collaboration revenue | – | – | – | – | – | – | – | $177.39K | $2.88M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Jaguar Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.